Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, November 2024
Hannah E. Reses, George Segovia, Heather Dubendris, Kira Barbre, Sushmitha Ananth, Brynn Lape-Newman, Emily Wong, Molly Stillions, Theresa A. Rowe, Elizabeth Mothershed, Erika Wallender, Evelyn Twentyman, Ryan E. Wiegand, Pragna Patel, Andrea L. Benin, Jeneita M. Bell
Abstract
Nursing home residents are at elevated risk for severe complications from respiratory viruses, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).Nursing homes are required to report COVID-19 vaccination coverage and can voluntarily report influenza and RSV vaccination coverage among residents to CDC's National Healthcare Safety Network.The purpose of this study was to assess COVID-19, influenza, and RSV vaccination coverage among nursing home residents early in the 2024-25 respiratory virus season.As of November 10, 2024, 29.7% of nursing home residents had received a 2024-2025 COVID-19 vaccine.Among residents at facilities that elected to report vaccination against influenza (59.4% of facilities) and RSV (51.8% of facilities), 58.4% had received influenza vaccination, and 17.9% had received RSV vaccination.Vaccination coverage varied by U.S. Department of Health and Human Services region, social vulnerability index level, and facility size.Addressing low coverage with COVID-19, influenza, and RSV vaccines is a priority to protect residents who are susceptible to severe outcomes associated with respiratory illnesses.* As of October 23, 2024, ACIP also recommends that persons aged 65 years and those who are moderately or severely immunocompromised receive a second dose of 2024-2025 COVID-19 vaccine 6 months after receipt of the first dose (https:// www.cdc.gov/covid/vaccines/stay-up-to-date.html).The data used for this study were collected <6 months after the 2024-2025 COVID-19 vaccine was released and reflect receipt of the first dose of 2024-2025 COVID-19 vaccine.